Recce Pharmaceuticals Ltd
ASX:RCE.AX
Overview | Financials
Company Name | Recce Pharmaceuticals Ltd |
Symbol | RCE.AX |
Currency | AUD |
Price | 0.475 |
Market Cap | 110,139,200 |
Dividend Yield | 0% |
52-week-range | 0.41 - 0.695 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. James Hamilton-Bray Graham GAICD |
Website | https://www.recce.com.au |
An error occurred while fetching data.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms.
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD